- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05345626
Vital Signs Monitoring in Rehabilitation Center Patients
It is Possible to Continuous Monitor Vital Signs in Patients Discharged a Rehabilitation Center - An Observational Feasibility Study
Study Overview
Status
Conditions
Detailed Description
Patients who are ready to leave the hospital but are deemed unable to return home are discharged to a rehabilitation center to regain strength and performance.
Vital signs are only measured when deemed necessary at the rehabilitation center, in contrast to hospital wards, where vital signs are measured intermittently and manually every 8-12 hours.
Wearable devices that continuously monitor a patient's vital signs may be able to detect patients who are deteriorating, as abnormal vital signs often precede a physiologic decline This study aims to determine whether it is possible to continuously monitor patients discharged to a rehabilitation center and detect more abnormal vital signs than measurements from the rehabilitation center. By attaching three wearable devices to 20 patients, we wished to record the vital signs for up to 96 hours, documenting abnormal vital signs as well as complications - and readmission rates.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Brønshøj, Denmark, 2700
- Center for Rehabilitering og Akutpleje - Bystævneparken
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- discharged to the rehabilitation center after surgery or; diagnosed with ischemic heart disease, chronic heart disease, apoplexia cerebri, chronic obstructive pulmonary disease, or diabetes.
- Inclusion less than 72 h from rehabilitation admission
Exclusion Criteria:
- Unable to give informed consent
- Implanted pacemaker or cardioverter-defibrillator
- allergic to plaster, plastic, silicone
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Monitoring time
Time Frame: 96 hours
|
Monitoring time with data from any device
|
96 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SpO2 < 92%
Time Frame: 96 hours
|
Duration of SpO2 < 92%
|
96 hours
|
|
SpO2 < 88%
Time Frame: 96 hours
|
Duration of SpO2 < 88%
|
96 hours
|
|
SpO2 < 85%
Time Frame: 96 hours
|
Duration of SpO2 < 85%
|
96 hours
|
|
SpO2 < 80%
Time Frame: 96 hours
|
Duration of SpO2 < 80%
|
96 hours
|
|
Respiratory rate <5 breaths per minute
Time Frame: 96 hours
|
Duration of respiratory rate <5 breaths per minute
|
96 hours
|
|
Respiratory rate <11 breaths per minute
Time Frame: 96 hours
|
Duration of respiratory rate <11 breaths per minute
|
96 hours
|
|
Respiratory rate >24 breaths per minute
Time Frame: 96 hours
|
Duration of respiratory rate >24 breaths per minute
|
96 hours
|
|
Respiratory rate >30 breaths per minute
Time Frame: 96 hours
|
Duration of respiratory rate >30 breaths per minute
|
96 hours
|
|
Heart rate <30 beats per minute
Time Frame: 96 hours
|
Duration of heart rate <30 beats per minute
|
96 hours
|
|
Heart rate <40 beats per minute
Time Frame: 96 hours
|
Duration of heart rate <40 beats per minute
|
96 hours
|
|
Heart rate > 110 beats per minute
Time Frame: 96 hours
|
Duration of heart rate > 110 beats per minute
|
96 hours
|
|
Heart rate > 130 beats per minute
Time Frame: 96 hours
|
Duration of heart rate > 130 beats per minute
|
96 hours
|
|
Systolic blood pressure <70 mmHg
Time Frame: 96 hours
|
Number of systolic blood pressure <70 mmHg measurements
|
96 hours
|
|
Systolic blood pressure <90 mmHg
Time Frame: 96 hours
|
Number of systolic blood pressure <90 mmHg measurements
|
96 hours
|
|
Systolic blood pressure >180 mmHg
Time Frame: 96 hours
|
Number of systolic blood pressure >180 mmHg measurements
|
96 hours
|
|
Systolic blood pressure >220 mmHg
Time Frame: 96 hours
|
Number of systolic blood pressure >220 mmHg measurements
|
96 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complication
Time Frame: 30 days
|
Complication frequency within 30 days from study inclusion
|
30 days
|
|
Readmission
Time Frame: 30 days
|
Readmission frequency within 30 days from study inclusion
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eske K Aasvang, Dr. Med, Rigshospitalet, Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Rigshospitalet, Copenhagen
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Comorbidities
-
Masimo CorporationCompletedVarious ComorbiditiesUnited States
-
National Minority Quality ForumRecruitingCancer | Cancer ComorbiditiesUnited States
-
Rajiv Gandhi Cancer Institute & Research Center...CompletedComorbidities and Coexisting ConditionsIndia
-
Wake Forest University Health SciencesCompletedComorbidities and Coexisting ConditionsUnited States
-
Cogito Health IncNational Institute of Mental Health (NIMH); Brigham and Women's Hospital; Partners...CompletedBehavioral Health With Medical ComorbiditiesUnited States
-
Rigshospitalet, DenmarkActive, not recruitingLiver Transplantation | Comorbidities and Coexisting ConditionsDenmark
-
General Practitioners Research InstituteBoehringer IngelheimCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdolescents With Obesity or Overweight With Weight-Related ComorbiditiesChina
-
Hanmi Pharmaceutical Company LimitedCompletedType2 Diabetes | Obese With Comorbidities | Overweight With ComorbiditiesUnited States
-
Instituto Aragones de Ciencias de la SaludAndaluz Health Service; Instituto de Salud Carlos III; Red de Investigación en... and other collaboratorsCompletedMultimorbidity | Polypharmacy | Comorbidities and Coexisting Conditions | Clinical Decision-Support SystemsSpain